Literature DB >> 21907637

Prevalence and impact on FEV(1) decline of chronic methicillin-resistant Staphylococcus aureus (MRSA) colonization in patients with cystic fibrosis. A single-center, case control study of 165 patients.

E Vanderhelst1, L De Meirleir, S Verbanck, D Piérard, W Vincken, A Malfroot.   

Abstract

BACKGROUND: Risk factors for methicillin-resistant Staphylococcus aureus (MRSA) in Cystic Fibrosis (CF) and the impact on CF disease progression are still under debate. The objectives of this study were to determine clinical variables associated with MRSA colonization and examine impact on FEV(1) evolution in CF patients.
METHODS: A retrospective case-control study using the University Hospital of Brussels CF clinic patient registry from 2002 to 2010, comparing clinical variables and decline of FEV(1) of MRSA positive patients with age and sex matched controls, chronically colonized with S. aureus.
RESULTS: Thirty of the 165 CF patients, chronically colonized with S. aureus, had cultures positive for MRSA (18.2%). Excluding patients under 4 years, the prevalence became 15.2% (23/151). Chronic colonization (i.e., three or more consecutive positive cultures) was found in 19/151 (12.6%). The MRSA positive group showed a higher proportion of patients with genotype F508del, less pancreas sufficient patients, more bronchiectasis and more frequent hospitalization. The FEV(1) recorded one year prior to, and at the moment of MRSA acquisition, was lower but not significantly different from that obtained in controls (72.9%±26.6 vs 84.3±21.8 and 68.2%±27.1 vs 81.4%±24.3 respectively, p>0.1). However, FEV(1) decline over 2- and 6-year periods, were significantly greater in the chronic MRSA group than in the controls (-5%±5.5 vs -2.5±2.3 over 2 years (p=0.043) and -1.8%±4.6 vs -1.0%±1.9 over a 6-year period (p=0.026)).
CONCLUSION: In our center the prevalence of MRSA in CF patients, chronically colonized with S. aureus and over the age of 4 years, was 15.2% (12.6% chronic infection). MRSA colonization was shown to be associated with a genotype F508del, presence of bronchiectasis and hospitalization. Our spirometric data also show that a MRSA episode entails an FEV(1) decline that is almost double that predicted for CF patients who can remain unaffected by MRSA.
Copyright © 2011 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21907637     DOI: 10.1016/j.jcf.2011.08.006

Source DB:  PubMed          Journal:  J Cyst Fibros        ISSN: 1569-1993            Impact factor:   5.482


  10 in total

1.  Area Deprivation as a Risk Factor for Methicillin-resistant Staphylococcus aureus Infection in Pediatric Cystic Fibrosis.

Authors:  Gabriela R Oates; William T Harris; Steven M Rowe; George M Solomon; Suranjana Dey; Aowen Zhu; Wynton C Hoover; Hector H Gutierrez
Journal:  Pediatr Infect Dis J       Date:  2019-11       Impact factor: 2.129

2.  Staphylococcus aureus Potentiates the Hemolytic Activity of Burkholderia cepacia Complex (Bcc) Bacteria.

Authors:  Alessandro Moriano; Diego O Serra; Amparo Hoard; Sabrina Montaña; Jose Degrossi; Robert A Bonomo; Krisztina M Papp-Wallace; Maria Soledad Ramirez
Journal:  Curr Microbiol       Date:  2021-03-26       Impact factor: 2.188

3.  Phase I, Dose-Escalating Study of the Safety and Pharmacokinetics of Inhaled Dry-Powder Vancomycin (AeroVanc) in Volunteers and Patients with Cystic Fibrosis: a New Approach to Therapy for Methicillin-Resistant Staphylococcus aureus.

Authors:  Grant Waterer; John Lord; Thomas Hofmann; Taneli Jouhikainen
Journal:  Antimicrob Agents Chemother       Date:  2020-02-21       Impact factor: 5.191

4.  Molecular epidemiology of methicillin-resistant Staphylococcus aureus isolated in serial cultures from the respiratory tract of children with cystic fibrosis.

Authors:  Duha Al-Zubeidi; Patrick G Hogan; Mary Boyle; Carey-Ann D Burnham; Stephanie A Fritz
Journal:  Pediatr Infect Dis J       Date:  2014-06       Impact factor: 2.129

5.  Host response to Staphylococcus aureus cytotoxins in children with cystic fibrosis.

Authors:  Ashley D Chadha; Isaac P Thomsen; Natalia Jimenez-Truque; Nicole R Soper; Lauren S Jones; Andrew G Sokolow; Victor J Torres; C Buddy Creech
Journal:  J Cyst Fibros       Date:  2016-01-25       Impact factor: 5.482

6.  MRSA eradication of newly acquired lower respiratory tract infection in cystic fibrosis.

Authors:  Emilie Vallières; Jacqueline C Rendall; John E Moore; John McCaughan; Anne I Hoeritzauer; Michael M Tunney; Joseph Stuart Elborn; Damian G Downey
Journal:  ERJ Open Res       Date:  2016-03-15

7.  Time-Resolved Tracking of Mutations Reveals Diverse Allele Dynamics during Escherichia coli Antimicrobial Adaptive Evolution to Single Drugs and Drug Pairs.

Authors:  Rachel A Hickman; Christian Munck; Morten O A Sommer
Journal:  Front Microbiol       Date:  2017-05-24       Impact factor: 5.640

Review 8.  Interventions for the eradication of meticillin-resistant Staphylococcus aureus (MRSA) in people with cystic fibrosis.

Authors:  David Kh Lo; Marianne S Muhlebach; Alan R Smyth
Journal:  Cochrane Database Syst Rev       Date:  2018-07-21

9.  Factors Influencing Lung Function in Patients with Cystic Fibrosis in Western Romania.

Authors:  Mihaela Dediu; Ioana Mihaiela Ciuca; Monica Steluta Marc; Estera Boeriu; Liviu Laurentiu Pop
Journal:  J Multidiscip Healthc       Date:  2021-06-15

10.  Incidence and treatment of methicillin-resistant S. aureus infection in cystic fibrosis patients: a cohort study.

Authors:  Paloma Horejs Bittencourt; Carlos Sidney Silva Pimentel; Bianca Sampaio Bonfim; Paulo José Marostica; Edna Lúcia Souza
Journal:  Braz J Infect Dis       Date:  2016-10-15       Impact factor: 3.257

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.